Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORTREL 1/35-21 vs MICROGESTIN 1.5/30
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Oral contraception
Prevention of pregnancy,Acne vulgaris (off-label, for women who desire contraception and have not responded to topical therapy),Dysmenorrhea (off-label),Endometriosis (off-label),Menorrhagia (off-label),Functional ovarian cysts (off-label)
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-19 hours. Steady-state reached within 5-7 days.
Ethinyl estradiol undergoes hepatic metabolism primarily via CYP3A4 hydroxylation and conjugation; norethindrone is metabolized primarily via reduction and sulfate/glucuronide conjugation.
No dose adjustment required for renal impairment; use with caution in severe impairment.
No dose adjustment is required for patients with renal impairment. However, because of potential fluid retention, use with caution in patients with renal dysfunction.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day) and is significant in women over 35. Women over 35 who smoke should not use this product.
Category X. First trimester: No increased risk of major birth defects observed in clinical studies, but postmarketing data are insufficient. Second and third trimesters: Use associated with fetal harm, including cardiovascular defects, limb defects, and masculinization of female fetuses. Avoid during pregnancy.
First trimester: An increased risk of cardiovascular defects and oral clefts following first-trimester exposure to oral contraceptives has been suggested but not confirmed. Norethindrone and ethinyl estradiol are not recommended during pregnancy. If pregnancy occurs, the drug should be discontinued. Second and third trimesters: Exposure to estrogens and progestins may cause fetal harm, including urogenital abnormalities in female fetuses (e.g., hypospadias in males, clitoral enlargement, labial fusion in females). Use is contraindicated during known or suspected pregnancy.
Nortrel 1/35-21 is a monophasic combined oral contraceptive containing 1 mg norethindrone and 35 mcg ethinyl estradiol. Administer 21 active tablets followed by 7 placebo tablets. Advise patients to take at the same time daily. Missed doses increase pregnancy risk; use backup contraception if missed. Not recommended in patients with BMI > 35 due to increased failure risk. Contraindicated in smokers over 35 years old.
MICROGESTIN 1.5/30 (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) is a monophasic combined oral contraceptive. Its progestin component has mild androgenic activity, which may benefit some women with acne. Bleeding irregularities are common in the first 3 cycles. Counsel patients that missing pills increases pregnancy risk; strict adherence is critical. Evaluate baseline blood pressure and consider stopping if migraine with aura develops. Liver enzyme inducers (e.g., rifampin, certain anticonvulsants) may reduce efficacy.
No interactions on record
No interactions on record
NORTREL 1/35-21 and MICROGESTIN 1.5/30 are distinct pharmacological agents. NORTREL 1/35-21 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyOral contraception. MICROGESTIN 1.5/30 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyAcne vulgaris (off-label, for women who desire contraception and have not responded to topical therapy)Dysmenorrhea (off-label)Endometriosis (off-label)Menorrhagia (off-label)Functional ovarian cysts (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. NORTREL 1/35-21 carries a safety status of Category C, whereas MICROGESTIN 1.5/30 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Norethindrone acetate is deacetylated to norethindrone, primarily metabolized via cytochrome P450 3A4 (CYP3A4) to reduced metabolites, sulfates, and glucuronides. Ethinyl estradiol is metabolized primarily by CYP3A4, undergoes hydroxylation, and undergoes conjugation (glucuronidation and sulfation). Both undergo enterohepatic recirculation.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Renal: ~50-60% (primarily as glucuronide conjugates of ethinyl estradiol and norethindrone); Fecal: ~40-50% (via biliary elimination)
Norethindrone: 80% bound to albumin and SHBG; Ethinyl estradiol: 98% bound to albumin and SHBG.
Norethindrone: 90-95% bound to SHBG and albumin; Ethinyl estradiol: 95-98% bound to albumin, with 2-5% free.
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 3-5 L/kg. Indicates extensive tissue distribution.
Norethindrone: 3-5 L/kg; Ethinyl estradiol: 2-4 L/kg. High Vd indicates extensive tissue distribution.
Oral: Norethindrone ~65% (first-pass metabolism), Ethinyl estradiol ~40-50% (first-pass metabolism).
Oral: Norethindrone ~64-75%; Ethinyl estradiol ~45-60% due to first-pass metabolism.
Contraindicated in acute liver disease, hepatocellular carcinoma, or active hepatitis. In Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Contraindicated in patients with acute liver disease or hepatocellular carcinoma. For Child-Pugh class A: use with caution; class B or C: not recommended due to potential for impaired hormone metabolism.
Not indicated for use before menarche; after menarche, same as adult dosing.
Safety and effectiveness in pediatric patients under 18 years have not been established. Not indicated for use before menarche.
No specific dose adjustment; estrogen-containing contraceptives are generally not recommended after menopause.
Not indicated for use in postmenopausal women. No specific dosing recommendations in elderly; evaluate risk-benefit considering comorbidities (e.g., cardiovascular disease).
Cigarette smoking increases risk of serious cardiovascular events (thrombophlebitis, venous thromboembolism, stroke, myocardial infarction) from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (venous thromboembolism, arterial thrombosis), stroke, myocardial infarction, especially in smokers >35 years. Hepatic neoplasia (benign and malignant), hypertension, gallbladder disease, carbohydrate/lipid effects, headache/migraine exacerbation, visual disturbances (retinal thrombosis). Breakthrough bleeding/spotting. Hepatic enzyme induction (e.g., rifampin) may reduce contraceptive efficacy.
Active or history of thrombophlebitis or thromboembolic disorders. Cerebrovascular or coronary artery disease. Known or suspected pregnancy. Undiagnosed abnormal uterine bleeding. Known or suspected breast carcinoma or other estrogen-/progestin-sensitive neoplasia. Hepatic adenoma or carcinoma. Jaundice or cholestatic jaundice of pregnancy, or history of jaundice with prior oral contraceptive use. Acute or chronic hepatocellular disease with abnormal liver function. Heavy smoking (≥15 cigarettes/day) in women >35 years. Hypersensitivity to any component.
No specific food restrictions; however, grapefruit juice may increase estrogen levels; avoid excessive consumption. Maintain consistent dietary patterns to avoid gastrointestinal interference with absorption.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but no specific restriction. Consistent dietary habits are recommended to avoid cycle irregularities.
Excreted in breast milk in small amounts; M/P ratio for estrogen is 0.2, for progestin is 0.3. No adverse effects reported in nursing infants. American Academy of Pediatrics considers use compatible with breastfeeding, but may reduce milk production and quality. Use only if clearly needed.
Small amounts of oral contraceptive steroids (including norethindrone and ethinyl estradiol) are excreted in breast milk. The M/P ratio is approximately 0.5 for norethindrone and 0.01–0.02 for ethinyl estradiol. Use during lactation may decrease milk production and quality. Not recommended for use in nursing mothers until weaning is complete. Alternative methods of contraception should be considered.
No dose adjustment required; drug is contraindicated in pregnancy. If inadvertently used, discontinue immediately.
No dosing adjustment is applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) are not relevant since use is contraindicated. Inadvertent exposure should prompt discontinuation and evaluation.
Take one pill at the same time each day, starting on the first day of your menstrual period.,If you miss a dose, take it as soon as remembered, and use a backup method for 7 days.,Do not smoke while taking this medication, especially if over 35 years old.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Inform your doctor if you have liver disease, blood clots, breast cancer, or high blood pressure.
Take one tablet daily at the same time to maintain steady hormone levels.,If you miss a pill, refer to the package insert: take the missed pill as soon as remembered and use backup contraception (e.g., condoms) for 7 days.,Common side effects include nausea, breast tenderness, and spotting; these often improve after 3 cycles.,Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old and smoking 15+ cigarettes daily.,Seek emergency care for leg pain/swelling, sudden severe headache, chest pain, or vision changes (possible blood clot or stroke).